Quidelortho Corp last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 27, 2026): revenue of $618.9 million (-11.6% year over year) and diluted EPS of -$0.78. It usually reports 17–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 10, 2027.
Results for Q4 FY2026, the quarter ending around Dec 27, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 11, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 17–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
37 days after quarter end
|
Q3 FY2026
ended Sep 27, 2026
|
619
-11.6%
|
-54
+92.7%
|
-0.78
+92.8%
|
|
Aug 6, 2026
39 days after quarter end
|
Q2 FY2026
ended Jun 28, 2026
|
631
+2.8%
|
-93
+63.6%
|
-1.36
+63.9%
|
|
Apr 15, 2026
17 days after quarter end
|
Q1 FY2026
ended Mar 29, 2026
|
620
-10.5%
|
-92
-622.8%
|
-1.35
-610.5%
|
|
Feb 11, 2026
45 days after quarter end
|
Q4 FY2025
ended Dec 28, 2025
|
724
+2.2%
|
-131
+26.7%
|
-1.92
+27.4%
|
|
Nov 5, 2025
38 days after quarter end
|
Q3 FY2025
ended Sep 28, 2025
|
700
-3.7%
|
-733
-3583.4%
|
-10.78
-3493.3%
|
|
Aug 5, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 29, 2025
|
614
-3.6%
|
-255
-72.9%
|
-3.77
-71.4%
|
|
May 7, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 30, 2025
|
693
-2.6%
|
-13
+99.3%
|
-0.19
+99.3%
|
|
Jan 13, 2025
15 days after quarter end
|
Q4 FY2024
ended Dec 29, 2024
|
708
-4.7%
|
-178
-2648.6%
|
-2.64
-2622.2%
|
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QDEL (Nasdaq)
- Fiscal year ends
- January 1
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1906324
- Former names
- Coronado Topco, Inc. (until Apr 11, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.